Similar Articles

Home | Newsletter | My Articles | My Account | Help

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 8, 2011 Rich Smith	What's All the Fuss About Zalicus? Stock's up on an Oppy upgrade.
The Motley Fool August 15, 2011 Jim Royal	6 Wild Bets on Biotech Riches The most interesting biotech tickers.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool September 6, 2011 Brian Orelli	Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game?
The Motley Fool September 30, 2011 David Williamson	4 Health-Care Stocks Worth Watching Four companies our analysts are watching ahead of earnings.